Welcome to LookChem.com Sign In|Join Free

CAS

  • or
C18H14BrN3O is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1600515-57-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1600515-57-8 Structure
  • Basic information

    1. Product Name: C18H14BrN3O
    2. Synonyms:
    3. CAS NO:1600515-57-8
    4. Molecular Formula:
    5. Molecular Weight: 368.233
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1600515-57-8.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C18H14BrN3O(CAS DataBase Reference)
    10. NIST Chemistry Reference: C18H14BrN3O(1600515-57-8)
    11. EPA Substance Registry System: C18H14BrN3O(1600515-57-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1600515-57-8(Hazardous Substances Data)

1600515-57-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1600515-57-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,0,0,5,1 and 5 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1600515-57:
(9*1)+(8*6)+(7*0)+(6*0)+(5*5)+(4*1)+(3*5)+(2*5)+(1*7)=118
118 % 10 = 8
So 1600515-57-8 is a valid CAS Registry Number.

1600515-57-8Downstream Products

1600515-57-8Relevant articles and documents

Discovery of 4-anilino α-carbolines as novel Brk inhibitors

Mahmoud, Kazem Ahmed,Krug, Martin,Wersig, Tom,Slynko, Inna,Sch?chtele, Christoph,Totzke, Frank,Sippl, Wolfgang,Hilgeroth, Andreas

, p. 1948 - 1951 (2014/04/17)

Dysregulation of cell signalling processes caused by an enhanced activity of protein kinases mainly contributes to cancer progression. Protein kinase inhibitors have been established as promising drugs that inhibit such overactive protein kinases in cancer cells. The formation of metastases, which makes a therapy difficult, remains a great challenge for cancer treatment. Recently, breast tumor kinase (Brk) was discovered as novel and interesting target for a cancer therapy because Brk participates in both cell dysregulation and metastasis. We discovered 4-anilino substituted α-carboline compounds as a novel class of highly active Brk inhibitors. In the current work, structure-activity relationships are discussed including docking results obtained for 4-anilino α-carbolines. A first profiling of selective kinase inhibition and a proof of concept for the antiproliferative effects is demonstrated. These results qualify the compounds as a promising class of novel antitumor agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1600515-57-8